Clinical Trial Update: Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating enfortumab vedotin as monotherapy in metastatic castration-resistant prostate cancer; trial is currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING